Eleana Tsoumani
Research Subjects
Eleana Tsoumani has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Agnes Brandtmüller
MS, MSD, Budapest, Hungary
3 shared publications - Andrea Favre-Bulle
MSD Switzerland
3 shared publications - Kwame Owusu-Edusei
Merck & Co., Inc., Rahway, New Jersey, USA
3 shared publications Thomas Mutschler
MSD Switzerland
3 shared publications- Ahmad Abbadi
Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Solna, Sweden
2 shared publications - Amaia Calderón-Larrañaga
Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
Cost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccine in the Netherlands
Background: The Netherlands currently uses the 15-valent pneumococcal conjugate vaccine (PCV15) in a 2 + 1 schedule in its pediatric national immunization program. The European Medicines Agency recently approved the use of 20-valent PCV (PCV20) in a 3 + 1 schedule for the prevention of pneumococcal disease in children. This study evaluates the cost-effectiveness of routine childhood immunization with PCV20 (3 + 1) versus PCV15 (2 + 1) in the Netherlands. Methods: A decision-analytic Markov model was used to track the health (pneumococcal disease, sequelae, and death) and economic (treatment costs and indirect costs, including productivity losses) outcomes of a single birth cohort of 165,977 infants over their lifetimes starting in 2025. Disease incidence, vaccination rates, and vaccine effectiveness were derived from published sources, and indirect effects, such as herd protection, were included. The model adopted a societal perspective, with costs adjusted to 2025 euros and discounted at 3.0%. Scenario and sensitivity analyses were used to assess the effects of variation in input parameters. Results: In the base case, compared to PCV15, PCV20 prevented 139 more cases of invasive pneumococcal disease, 638 more pneumonia cases, 3,393 more cases of acute otitis media, and 3 more episodes of post-meningeal sequelae over a lifetime horizon at an additional cost of €13,201,279. With 24 quality-adjusted life-years (QALYs) gained by vaccination with PCV20 vs. PCV15, the incremental cost-effectiveness ratio was €530,629/QALY, well above the Dutch willingness-to-pay threshold of €20,000–80,000/QALY. Conclusion: Routine childhood immunization with PCV20 instead of PCV15 is not cost-effective in the Netherlands.
- 17 November 2026
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
Open AccessCost-effectiveness analysis of routine childhood immunization with 20-valent versus 15-valent pneumococcal conjugate vaccine in the Netherlands
Background: The Netherlands currently uses the 15-valent pneumococcal conjugate vaccine (PCV15) in a 2 + 1 schedule in its pediatric national immunization program. The European Medicines Agency recently approved the use of 20-valent PCV (PCV20) in a 3 + 1 schedule for the prevention of pneumococcal disease in children. This study evaluates the cost-effectiveness of routine childhood immunization with PCV20 (3 + 1) versus PCV15 (2 + 1) in the Netherlands. Methods: A decision-analytic Markov model was used to track the health (pneumococcal disease, sequelae, and death) and economic (treatment costs and indirect costs, including productivity losses) outcomes of a single birth cohort of 165,977 infants over their lifetimes starting in 2025. Disease incidence, vaccination rates, and vaccine effectiveness were derived from published sources, and indirect effects, such as herd protection, were included. The model adopted a societal perspective, with costs adjusted to 2025 euros and discounted at 3.0%. Scenario and sensitivity analyses were used to assess the effects of variation in input parameters. Results: In the base case, compared to PCV15, PCV20 prevented 139 more cases of invasive pneumococcal disease, 638 more pneumonia cases, 3,393 more cases of acute otitis media, and 3 more episodes of post-meningeal sequelae over a lifetime horizon at an additional cost of €13,201,279. With 24 quality-adjusted life-years (QALYs) gained by vaccination with PCV20 vs. PCV15, the incremental cost-effectiveness ratio was €530,629/QALY, well above the Dutch willingness-to-pay threshold of €20,000–80,000/QALY. Conclusion: Routine childhood immunization with PCV20 instead of PCV15 is not cost-effective in the Netherlands.
- Open Access
- 10 September 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2283-2294
Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
Pneumococcal disease (PD) collectively describes Streptococcus pneumoniae infections at various anatomical sites1,2. Infections of usually sterile sites are classified as invasive pneumococcal dise...
- 10 September 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2283-2294
Open AccessCost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21
Pneumococcal disease (PD) collectively describes Streptococcus pneumoniae infections at various anatomical sites1,2. Infections of usually sterile sites are classified as invasive pneumococcal dise...
- Open Access
- 17 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 334-344
Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland
This study evaluated the health and economic impacts of the 21-valent pneumococcal conjugate vaccine (PCV21) compared to the 20-valent pneumococcal conjugate vaccine (PCV20) in Swiss adults aged 65 years and older using the delta-price approach. A published state-transition Markov model was used to track health and economic outcomes of invasive pneumococcal disease (IPD), inpatient non-bacteremic pneumococcal pneumonia (NBPP), and post-meningitis sequelae (PMS). Estimated quality-adjusted life years (QALYs)and cost outcomes were discounted at 3%. All costs were presented in 2024 Swiss Franc (CHF). Price premiums were estimated as the difference between the prices of PCV21 and PCV20, and the maximum premiums at which PCV21 remains cost-saving and cost-effective (at a willingness-to-pay threshold of CHF 40,000) were reported. A scenario analysis was conducted to include a pneumococcal polysaccharide vaccine 23-valent (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) vaccine-experienced population. Sensitivity analysis identified the input categories that were most influential on the price premiums. Overall, PCV21 averted more cases of IPD, NBPP, PMS and associated deaths, and saved more direct costs than PCV20. Compared to PCV20, PCV21 was cost-saving until a price premium of CHF 25.10 and cost-effective up to a price premium of CHF 88.01. In the scenario analysis, PCV21 was cost-saving up to a price premium of CHF 25.38, and cost-effective up to a price premium of CHF 88.68. Vaccine effectiveness and disease costs were the most influential inputs on the price premiums. PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.
- 17 February 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 334-344
Open AccessDelta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in Switzerland
This study evaluated the health and economic impacts of the 21-valent pneumococcal conjugate vaccine (PCV21) compared to the 20-valent pneumococcal conjugate vaccine (PCV20) in Swiss adults aged 65 years and older using the delta-price approach. A published state-transition Markov model was used to track health and economic outcomes of invasive pneumococcal disease (IPD), inpatient non-bacteremic pneumococcal pneumonia (NBPP), and post-meningitis sequelae (PMS). Estimated quality-adjusted life years (QALYs)and cost outcomes were discounted at 3%. All costs were presented in 2024 Swiss Franc (CHF). Price premiums were estimated as the difference between the prices of PCV21 and PCV20, and the maximum premiums at which PCV21 remains cost-saving and cost-effective (at a willingness-to-pay threshold of CHF 40,000) were reported. A scenario analysis was conducted to include a pneumococcal polysaccharide vaccine 23-valent (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) vaccine-experienced population. Sensitivity analysis identified the input categories that were most influential on the price premiums. Overall, PCV21 averted more cases of IPD, NBPP, PMS and associated deaths, and saved more direct costs than PCV20. Compared to PCV20, PCV21 was cost-saving until a price premium of CHF 25.10 and cost-effective up to a price premium of CHF 88.01. In the scenario analysis, PCV21 was cost-saving up to a price premium of CHF 25.38, and cost-effective up to a price premium of CHF 88.68. Vaccine effectiveness and disease costs were the most influential inputs on the price premiums. PCV21 provides greater health and economic benefits than PCV20 and is cost-effective over a range of price premiums.
- Open Access
- 1 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-10
Sex differences in the impact of lower respiratory tract infections on older adults’ health trajectories: a population-based cohort study
Background: Lower respiratory tract infections (LRTIs) are a major global health concern, particularly among older adults, who have an increased risk of poorer health outcomes that persist beyond the acute infectious episode. We aimed to investigate the mid-term (up to 7 years) and long-term (up to 12 years) effects of LRTIs on the objective health status trajectories of older adults, while also considering potential sex differences. Methods: Cohort data of adults aged ≥ 60 years from the Swedish National study of Aging and Care in Kungsholmen (SNAC-K) collected between 2001 and 2016 was analyzed. Information on LRTIs was obtained from the Swedish National Patient Register, and objective health status was assessed using the Health Assessment Tool (HAT) which incorporates indicators of mild and severe disability, cognitive and physical functioning, and multimorbidity. The LRTI-exposed and -unexposed participants were matched using propensity score matching based on an expansive list of potential confounders. Mixed linear models were used to analyze the association between LRTIs and changes in HAT scores. Results: The study included 2796 participants, 567 of whom were diagnosed with a LRTI. LRTIs were independently associated with an excess annual decline of 0.060 (95% CI: -0.107, -0.013) in the HAT score over a 7-year period. The associations were stronger among males, who experienced an excess annual decline of 0.108 (95% CI: -0.177, -0.039) in up to 7-years follow-up, and 0.097 (95% CI: -0.173, -0.021) in up to 12-years follow-up. The associations were not statistically significant among females in either follow-up period. Conclusion: LRTIs, even years after the acute infectious period, seem to have a prolonged negative effect on the health of older adults, particularly among males. Preventative public health measures aimed at decreasing LRTI cases among older adults could help in preserving good health and functioning in old age.
- 1 November 2024
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 24 (1) , 1-10
Open AccessSex differences in the impact of lower respiratory tract infections on older adults’ health trajectories: a population-based cohort study
Background: Lower respiratory tract infections (LRTIs) are a major global health concern, particularly among older adults, who have an increased risk of poorer health outcomes that persist beyond the acute infectious episode. We aimed to investigate the mid-term (up to 7 years) and long-term (up to 12 years) effects of LRTIs on the objective health status trajectories of older adults, while also considering potential sex differences. Methods: Cohort data of adults aged ≥ 60 years from the Swedish National study of Aging and Care in Kungsholmen (SNAC-K) collected between 2001 and 2016 was analyzed. Information on LRTIs was obtained from the Swedish National Patient Register, and objective health status was assessed using the Health Assessment Tool (HAT) which incorporates indicators of mild and severe disability, cognitive and physical functioning, and multimorbidity. The LRTI-exposed and -unexposed participants were matched using propensity score matching based on an expansive list of potential confounders. Mixed linear models were used to analyze the association between LRTIs and changes in HAT scores. Results: The study included 2796 participants, 567 of whom were diagnosed with a LRTI. LRTIs were independently associated with an excess annual decline of 0.060 (95% CI: -0.107, -0.013) in the HAT score over a 7-year period. The associations were stronger among males, who experienced an excess annual decline of 0.108 (95% CI: -0.177, -0.039) in up to 7-years follow-up, and 0.097 (95% CI: -0.173, -0.021) in up to 12-years follow-up. The associations were not statistically significant among females in either follow-up period. Conclusion: LRTIs, even years after the acute infectious period, seem to have a prolonged negative effect on the health of older adults, particularly among males. Preventative public health measures aimed at decreasing LRTI cases among older adults could help in preserving good health and functioning in old age.
- Open Access
- 17 July 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 36 (1) , 1-10
Impact of lower-respiratory tract infections on healthcare utilization and mortality in older adults: a Swedish population-based cohort study
Background: Lower respiratory tract infections (LRTIs) have an immediate significant impact on morbidity and mortality among older adults. However, the impact following the infectious period of LRTI remains understudied. We aimed to assess the short- to long-term impact of LRTIs on hospitalization, mortality, and healthcare utilization in older adults. Methods: Data from the Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was analyzed, with data from 2001 to 2019 for mortality and 2001–2016 for healthcare utilization. LRTI-exposed participants were identified and matched with LRTI-nonexposed based on sociodemographics, lifestyle factors, and functional and clinical characteristics. Statistical models evaluated post-LRTI hospitalization risk, days of inpatient hospital admissions, healthcare visits, and mortality. Results: 567 LRTIs-exposed participants during the study period and were matched with 1.701 unexposed individuals. LRTI-exposed individuals exhibited increased risk of hospitalization at 1-year (HR 2.14, CI 1.74, 2.63), 3-years (HR 1.74, CI 1.46, 2.07), and 5-years (HR 1.59, CI 1.33, 1.89). They also experienced longer post-LRTI hospital stays (IRR 1.40, CI 1.18, 1.66), more healthcare visits (IRR 1.47, CI 1.26, 1.71), specialist-care visits (IRR 1.46, CI 1.24, 1.73), and hospital admissions (IRR 1.57, CI 1.34, 1.83) compared to nonexposed participants over 16-years of potential follow-up. Additionally, the 19-year risk of mortality was higher among LRTI-exposed participants (HR 1.45, CI 1.24, 1.70). Men exhibited stronger associations with these risks compared to women. Conclusions: LRTIs pose both short- and long-term risks for older adults, including increased risks of mortality, hospitalization, and healthcare visits that transpire beyond the acute infection period, although these effects diminish over time. Men exhibit higher risks across these outcomes compared to women. Given the potential preventability of LRTIs, further public health measures to mitigate infection risk are warranted.
- 17 July 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 36 (1) , 1-10
Open AccessImpact of lower-respiratory tract infections on healthcare utilization and mortality in older adults: a Swedish population-based cohort study
Background: Lower respiratory tract infections (LRTIs) have an immediate significant impact on morbidity and mortality among older adults. However, the impact following the infectious period of LRTI remains understudied. We aimed to assess the short- to long-term impact of LRTIs on hospitalization, mortality, and healthcare utilization in older adults. Methods: Data from the Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was analyzed, with data from 2001 to 2019 for mortality and 2001–2016 for healthcare utilization. LRTI-exposed participants were identified and matched with LRTI-nonexposed based on sociodemographics, lifestyle factors, and functional and clinical characteristics. Statistical models evaluated post-LRTI hospitalization risk, days of inpatient hospital admissions, healthcare visits, and mortality. Results: 567 LRTIs-exposed participants during the study period and were matched with 1.701 unexposed individuals. LRTI-exposed individuals exhibited increased risk of hospitalization at 1-year (HR 2.14, CI 1.74, 2.63), 3-years (HR 1.74, CI 1.46, 2.07), and 5-years (HR 1.59, CI 1.33, 1.89). They also experienced longer post-LRTI hospital stays (IRR 1.40, CI 1.18, 1.66), more healthcare visits (IRR 1.47, CI 1.26, 1.71), specialist-care visits (IRR 1.46, CI 1.24, 1.73), and hospital admissions (IRR 1.57, CI 1.34, 1.83) compared to nonexposed participants over 16-years of potential follow-up. Additionally, the 19-year risk of mortality was higher among LRTI-exposed participants (HR 1.45, CI 1.24, 1.70). Men exhibited stronger associations with these risks compared to women. Conclusions: LRTIs pose both short- and long-term risks for older adults, including increased risks of mortality, hospitalization, and healthcare visits that transpire beyond the acute infection period, although these effects diminish over time. Men exhibit higher risks across these outcomes compared to women. Given the potential preventability of LRTIs, further public health measures to mitigate infection risk are warranted.
- Open Access
- 28 November 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (3) , 2279394
Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature
Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP's target populations more effectively.
- 28 November 2023
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 19 (3) , 2279394
Open AccessRecent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature
Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP's target populations more effectively.